Type 2 Diabetes

As the healthcare landscape has changed in recent years everyone from patients to doctors to pharmaceutical companies have had to change along with it.

When blood glucose levels prove difficult to control in patients with type 2 diabetes mellitus, it may be time to consider adding a third drug to the treatment regimen.

With a complicated condition like diabetes there is more to treatment than finding the right medication for patients. Providing the information they need and direction to help in their daily lives is also a key part of the overall picture.

There are a substantial number of factors physicians must take into consideration before starting a patient with type 2 diabetes mellitus on a particular treatment path. According to results from a recent study, the effectiveness of one of the most popular diabetes medications may be dependent on a patient's race or ethnicity.

With multiple factors hurting patients' chances of reaching type 2 diabetes treatment goals – including a lack of timely follow-up appointments and yo-yo blood glucose (A1C) levels – a respected physician recently advised a major shift in treatment, especially early on in the progressive disease.

Even adults with diabetes may be injecting insulin incorrectly which could put them at higher risk for additional conditions, according to lead author Paula M. Trief, PhD, of SUNY Upstate Medical Center.

With more than 10000 people in Boston for the American Diabetes Association's Scientific Sessions the event provides a chance for some of the top minds in the field to share information.

With so many people affected by diabetes finding the right treatment for the individual patients is becoming a key factor in care.

Pain levels due to diabetic peripheral neuropathy (DPN) may be altered depending on patients' vitamin D levels, a British study. The findings will be presented in a poster session on June 8 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.

DPP-4 inhibitors may also enhance beta cell function in patients with type 2 diabetes mellitus.

Diabetes researchers looked at the impact of chronic kidney disease on the glucose-regulating drug empagliflozin.

Results from a 104-week phase 3 study may have important implications for the way patients with type 2 diabetes mellitus tackle weight loss.

Insulin glargine, a commonly used treatment for type 2 diabetes mellitus, may be more effective when administered at a higher dose, according to results from a phase 3 study.

While medications go through extensive studies and research before being released to patients, the results in a controlled setting versus real-life situations may vary. Or do they?

Study results show that the combination of metformin and glibenclamide is as effective as insulin in achieving glycemic control in women with gestational diabetes and may be a more acceptable and cost effective therapy.

Researchers compared canagliflozin and sitagliptin treatment on HbA1c levels and body weight in patients with type 2 diabetes mellitus.

A rat study shows saxagliptin has promise for renal protection.

Empagliflozin, a diabetes drug that controls glucose levels, may also help ameliorate erectile dysfunction in patients with type 2 diabetes mellitus.

Approved by the US Food and Drug Administration (FDA) just over 4 years ago, linagliptin (Tradjenta) can help protect against renal injury in patients with type 2 diabetes.

Oxidative stress plays an important role in the ability for dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, to effectively ease diabetic nephropathy, according to lead author Takashi Hatanaka of Nagoya University. The study will be presented in a poster session on June 6 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.

The global pandemic of diabetes poses a huge public health challenge to every nation. In 2014 more than 380 million people around the world were living with diabetes-8.3% of the adult population. That number is expected to increase to 592 million by 2035.

Test your knowledge of empagliflozin, the newest SGLT2 inhibitor on the market.

A meta-analysis of peer-reviewed articles published after 2000 that looked at the economic consequences of type 2 diabetes mellitus treatment intensification produced several interesting findings.

With certain strains already proving to be resistant to treatment with antibiotics, Staphylococcus aureus is posing another major health threat.

We've been told that SGLT2 inhibitors only work on receptors in the kidneys, but a new study reveals a previously unknown function, as well as a new mechanism of action.

People who have type 2 diabetes —but not type 1— are statistically less likely to get amyotrophic lateral sclerosis (ALS), a new study found.

What’s around the corner? Take a peek at 4 technologies in progress aimed at improving diabetes management.

Danish researchers conducted a meta-analysis that looked at possible associations between coffee intake and obesity, metabolic syndrome, and type 2 diabetes. They reported finding only a low risk of these conditions in coffee drinkers, but no genetic variance to explain the relationships.

With the global boom in type 2 diabetes mellitus, many patients have greatest access to and are well-cared for by their primary care practitioners (PCPs). For those with basic, predictable, garden-variety diabetes, PCPs are perfectly capable of helping them. It's unclear when referral to a specialist for consultation or chronic management is most sensible.

Besides being the most common cause of chronic liver disease in industrialized nations, non-alcoholic fatty liver disease has serious hepatic consequences. It is expected to be the most frequent indication for liver transplantation by 2030.